Table 3.
The outcomes of this meta-analysis.
| Outcomes | Studies Numbers | Sample size | Overall effect | Heterogeneity | ||||
|---|---|---|---|---|---|---|---|---|
| Experiment | Control | Effect estimates | 95% CIs | P value | I 2 (%) | P value | ||
| Traditional Chinese medicine as the adjunctive therapy for COVID-19 | ||||||||
| Total effective | 8 | 484/569 | 347/549 | RR = 1.357 | 1.259-1.464 | P < 0.001 | 74.8% | P < 0.001 |
| Improvement of chest CT | 6 | 333/431 | 268/433 | RR = 1.249 | 1.143-1.356 | P < 0.001 | 0.0% | P = 0.571 |
| Fever improvement | 3 | 127/141 | 78/99 | RD = 0.110 | -0.063-0.283 | P = 0.213 | 84.1% | P = 0.002 |
| Cough improvement | 3 | 99/137 | 60/103 | RR = 1.288 | 1.057-1.570 | P = 0.012 | 0.0% | P = 0.466 |
| Conversion to severe cases | 5 | 30 of 480 | 72 of 460 | RR = 0.408 | 0.275-0.605 | P < 0.001 | 9% | P = 0.359 |
| The subgroup of Lianhua Qingwen as the adjunctive therapy for COVID-19 | ||||||||
| Total effective | 3 | 264/324 | 216/331 | RR = 1.248 | 1.136-1.371 | P < 0.001 | 0.0% | P = 0.686 |
| Improvement of chest CT | 3 | 252/324 | 210/331 | RR = 1.226 | 1.110-1.356 | P < 0.001 | 34.3% | P = 0.218 |
| Conversion to severe cases | 4 | 29/410 | 63/417 | RR = 0.469 | 0.311-0.707 | P < 0.001 | 0.0% | P = 0.748 |
Note: CIs = confidence intervals; RD = rate difference; OR = odds ratio.